Articles tagged with 'Magmaris' | BIOTRONIK

BIOTRONIK - Archive (Magmaris)

2020
15
November
2020
| 17:56 Europe/Amsterdam
 In their short time on the market, bioresorbable vascular scaffolds have generated plenty of discussion within interventional cardiology. According to the authors of “Fading Away or Hope for the Future,” published by the American College of Cardiolo...
Read more
2019
30
September
2019
| 00:00 Europe/Amsterdam
Full cohort data from the BIOSOLVE-IV registry strengthen the clinical evidence for BIOTRONIK’s Magmaris®1 Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery disease. Dr. Stefan Verheye, Senior Interventional Ca...
Read more
07
June
2019
| 00:00 Europe/Amsterdam
New data from the BIOSOLVE-IV registry strengthen the clinical evidence for the Magmaris®1 resorbable scaffold device and procedure success and safety profile at one year. Dr. Stefan Verheye, Senior Interventional Cardiologist at Antwerp Cardiovascul...
Read more
05
March
2019
| 00:00 Europe/Amsterdam
Preliminary data from the BIOSOLVE-IV registry strengthen the clinical evidence in favor of BIOTRONIK’s resorbable magnesium scaffold Magmaris®1 for de novo coronary artery lesions. Presented as late-breaking clinical data at the Cardiovascular Resea...
Read more
2018
24
September
2018
| 00:00 Europe/Amsterdam
Preliminary data from BIOSOLVE-IV registry shows low target lesion failure (TLF) rates of 4.3% with Magmarisa and only one case of scaffold thrombosis (after DAPT interruption before the event).1 The data presented at the TCT congress as late-brea...
Read more
14
June
2018
| 00:00 Europe/Amsterdam
Ever since its CE launch in June 2016, BIOTRONIK’s Magmaris has been implanted by more than 650 physicians in over 350 hospitals across 45 countries. As part of its Magnesium 2,000 program, a post-market evaluation program, more than 2,000 Magmaris c...
Read more
23
May
2018
| 00:00 Europe/Amsterdam
Data presented during the EuroPCR congress on the Magmaris Resorbable Magnesium Scaffold (RMS) provide further evidence on its continued safety and efficacy, also in a more complex population. Dr. Stefan Verheye, M.D., Ph.D., Senior Interventional...
Read more
2017
01
November
2017
| 00:00 Europe/Amsterdam
Data presented during the TCT congress on BIOTRONIK's Magmaris1 RMS provide further evidence on its continued safety and efficacy. Pooled 12-month data from the BIOSOLVE-II and BIOSOLVE-III clinical trials highlight high procedural success and the co...
Read more
31
October
2017
| 00:00 Europe/Amsterdam
Data presented at the BIOTRONIK-sponsored symposium on the Orsiro1 drug-eluting stent (DES) demonstrate why Orsiro is gaining prominence in the crowded DES market. In addition, clinical and preclinical data presented about Magmaris2 reinforce the cas...
Read more
17
May
2017
| 00:00 Europe/Amsterdam
BIOTRONIK’s Magmaris resorbable scaffold offers a reduced risk of thrombus formation compared to a polymeric scaffold*. Coordinating clinical investigator Dr. Michael Haude demonstrated during a latebreaking trial session at EuroPCR 2017 that there w...
Read more
16
May
2017
| 00:00 Europe/Amsterdam
Twentyfour month data from the BIOSOLVE-II study reveal the long-term safety, efficacy and stability of BIOTRONIK’s Magmaris resorbable magnesium scaffold. Presented during a late-breaking trial session at EuroPCR 2017, the findings demonstrated the ...
Read more
30
March
2017
| 00:00 Europe/Amsterdam
BIOTRONIK’s Magnesium 1,000 program has provided physicians an early post-market opportunity to evaluate the new resorbable Magmaris magnesium scaffold outside of clinical trials. Physicians reported very positive experiences, with 98.8% of scaffolds...
Read more